A commentary by Mark Feinberg, M.D., Ph.D., IAVI president and CEO
IAVI’s Dr. Jayanta Bhattacharya, of the Translational Health Science and Technology Institute, India, is interviewed by DBT/Wellcome Trust India All...
IAVI remembers Dr. Deepak Gaur, Deputy Country Director, India, and extends our deepest sympathies to his family.
This HIV Vaccine Awareness Day, we join the call for women to be at the center of the HIV response to lead their own solutions.
Scientists and community liaisons highlight the importance of collaboration in achieving an affordable, globally accessible HIV vaccine.
A spate of news coverage on the results of the Phase I IAVI G001 HIV vaccine clinical trial reflects current public interest in vaccine development ...
IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and bi...
Failure to meet commitments for TB research is not inevitable; the global COVID-19 response may show us the way.
IAVI CEO Mark Feinberg charts future HIV-1 vaccine development efforts in NEJM.
Results illuminate potential way forward for use of broadly neutralizing antibodies to prevent HIV
IAVI and partners recently held a webinar on challenges and opportunities for R&D of innovative biomedical treatments for COVID-19.